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Abstract
Obesity is a major and independent risk factor for cardiovascular disease and it is strongly associated with the development
of dyslipidemia, insulin resistance and type 2 diabetes. Flavonoids, a diverse group of polyphenol compounds of plant origin
widely distributed in human diet, have been reported to have numerous health benefits, although the mechanisms
underlying these effects have remained obscure. We analyzed the effects of chronic dietary supplementation with
flavonoids extracted from cranberry (FLS) in normal and obese C57/BL6 mice compared to mice maintained on the same
diets lacking FLS. Obese mice supplemented with flavonoids showed an amelioration of insulin resistance and plasma lipid
profile, and a reduction of visceral fat mass. We provide evidence that the adiponectin-AMPK pathway is the main mediator
of the improvement of these metabolic disorders. In contrast, the reduced plasma atherogenic cholesterol observed in
normal mice under FLS seems to be due to a downregulation of the hepatic cholesterol synthesis pathway. Overall, we
demonstrate for the first time that the molecular mechanisms underlying the beneficial effects of flavonoids are determined
by the metabolic state.
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Introduction
Flavonoids have been consumed in various forms throughout
the course of human existence. Over the last 20 years, these
diverse polyphenol compounds of plant origin have received
considerable attention due to their potential benefits to human
health [1]. Population studies have revealed an inverse correlation
between flavonoid intake from regular food and incidence of
several chronic diseases, including cardiovascular diseases (CVD)
[2]. Despite this, how flavonoids exert their effects has remained
poorly defined. A major focus has been on the antioxidant
properties of flavonoids, although they likely exert their effects
mainly through the modulation of signaling pathways and gene
expression [3–5]. A deeper understanding of the mechanisms of
flavonoid action in vivo is required to evaluate and better utilize
their potential for the treatment and prevention of human diseases.
Obesity is now recognized as a major contributor to multiple
health issues. Obesity has been strongly linked to dyslipidemia,
including elevated triglycerides (TG) and low density lipoproteins
(LDL), and low high density lipoproteins (HDL). Increased central
adiposity is also associated with microalbuminuria, inflammation,
hypertension, insulin resistance, and the risk for future diabetes.
Given these effects, obesity has also been implicated in the risk of
CVD [6]. These multiple metabolic abnormalities may derive
from increased adiposity in visceral fat depots as well as in
abnormal settings, such as liver and skeletal muscle. In addition to
energy storage, white adipose tissue is now understood as a critical
endocrine organ secreting adipokines, a large group of adipocyte-
derived signaling molecules diverse in their structure and function
[7]. Although many adipokines are thought to adversely affect
metabolism and promote inflammation, others may have protec-
tive actions. Adiponectin is an adipokine with anti-diabetic and
anti-atherogenic effects [8]. Adiponectin administration reverses
insulin resistance in lipoatrophic diabetic mice as well as in obese
and type 2 diabetic mouse models [8].
Flavonoids present in cranberry have shown many beneficial
effects, including the antidiabetic [4,9], antihypertensive [10], and
cardioprotective [9] effects of quercetin; antiobesity effects of
anthocyanins [11]; as well as the contribution of proanthocyani-
dins to the so-called ‘‘French paradox’’ [12]. As such, we
hypothesized that dietary supplementation with a cranberry
extract enriched in flavonoids (FLS) would have direct effects on
metabolic abnormalities associated with obesity and provide
health benefits under a normal metabolic status. Therefore, we
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or low-fat diets (HFD or LFD). Indeed, obese mice supplemented
with flavonoids showed an amelioration of insulin resistance and
plasma lipid profile, and a reduction of visceral fat mass. We
provide evidence that these effects might be mediated by the
activation of the adiponectin-AMPK pathway. On the other hand,
the reduced plasma atherogenic cholesterol observed in normal
mice under FLS seems to be due to a downregulation of the
hepatic cholesterol synthesis pathway. Therefore, our data suggest
that the molecular mechanisms underlying the flavonoid effects
depend upon the metabolic status.
Materials and Methods
Cranberry extract
A flavonoid extract was prepared from ‘90MX’ powder (Ocean
Spray Cranberries, Inc. Lakeville-Middleboro, MA, USA) as
previously described [13]. The composition of flavonoid extract, as
shown in Table S1, was determined by HPLC analysis [13] .
Animals and diets
Forty C57BL/6 male mice at 5 weeks of age were purchased from
The Jackson Laboratory (Bar Harbor, ME, USA) and maintained on
a standard chow diet for one week prior to the beginning of the study.
Mice were maintained in a temperature-controlled facility (25uC)
with a 12:12 light/dark cycle, and given both diet and water on an ad
libitum basis, except when fasting was required. At 6 weeks of age,
micewererandomlyassignedtotwogroupsandmaintainedeitheron
al o w - f a td i e t( L F D ;1 0 %e n e r g yf r o mf a t ;T a b l eS 2 )o ro nah i g h - f a t
diet (HFD; 60% energy from fat; TableS2) for 8 additional weeks (i.e.
until 14 weeks of age). We chose this experimental protocol to induce
obesity based on previously published reports [14,15]. Next, mice
were maintained either on the same dietary regimen (LFD or HFD)
or on the same diet supplemented with 2% of flavonoid extract
( L F D Co rH F D C )f o r1 0a d d i t i o n a lw e e k s( i . e .u n t i l2 4w e e k so fa g e ) .
Extract was added to the food in substitution of fiber and mixed to
homogeneity during the manufacturing of the diets (TestDiet,
Richmond, IN, USA). We chose the extract concentration based
on pilot experiments performed with different concentrations
dissolved in water or mixed with food. 2% of flavonoid extract was
the maximum concentration achieved that did not alter food intake
and/or exhibit obvious negative side effects. The weight of the mice
a n df o o di n t a k ew e r er e c o r d e do naw e e k l yb a s i s .B o d yc o m p o s i t i o n
analysis (by PIXImus DEXA scan, [16]) and glucose tolerance test
(GTT) were performed on subgroups of mice at 14 and 24 weeks of
age. Subsequently, mice were fasted overnight (16 hrs) and sacrificed
to collect serum and tissues. At the time of sacrifice, selected organs,
including liver, muscle, visceral fat and mesenteric fat, were dissected
and weighed. All tissue samples and serum were frozen immediately
and kept at 280uC for further analysis. All animal experiments were
conducted inaccordance with the National InstitutesofHealth Guide
for the Care and Use of Laboratory Animals [17] and were approved
by the Rutgers University Institutional Committee on Animal Care
(protocol no. 05-009).
Serum parameters
Serum levels of non-esterified fatty acids (NEFA), triglycerides
(TG), total and HDL cholesterol (T-C and HDL-C) were
measured using the HR Series NEFA-HR(2), L-Type TG H,
Cholesterol E, and HDL-Cholesterol E kits, respectively (Wako
Chemicals, Richmond, VA, USA). Atherogenic cholesterol (non-
HDL) was estimated by subtracting HDL-C from T-C [18].
Insulin, leptin, resistin, and adiponectin were measured using
Ultra-sensitive Rat/mouse insulin assay (Crystal Chem, Downers
Grove IL, USA), Mouse Leptin Immunoassay kit (R&D System,
Minneapolis, MN, USA), Resistin (murine) EIA Kit (Cayman
Chemical Company, Ann Arbor, MI, USA), and Adiponectin
(Mouse) EIA kit (ALPCO, Salem, NH, USA).
Tissue lipid concentration
Total lipids from liver and muscle samples were extracted
according to the Folch extraction protocol [19]. The extracts
dissolved in chloroform with 2% Triton X100 were evaporated
under nitrogen and dissolved in water (for TG and FA) or
isopropanol (for cholesterol), followed by measurement of TG,
total cholesterol and FA using L-Type TG H, Cholesterol E,
and HR Series NEFA-HR(2) kits, respectively (Wako Chemicals,
Richmond, VA, USA) [20].
Western blot analysis
Monoclonal rabbit anti-mouse AMPKa and Phospho-AMPKa
(Thr172) antibodies (CellSignaling Technology, Danver,MA, USA),
goat anti-mouse LDL receptor (LDLR) (R&D Systems, Inc.,
Minneapolis, MN, USA), rat monoclonal anti-human/mouse
(specific for full-length protein) and monoclonal anti-mouse Adipo-
nectin/Acr30 antibodies (for full-length and truncated proteins)
(R&D System Inc., Minneapolis, MN, USA), rabbit polyclonal anti-
b-tubulin antibody (IMGENEY, San Diego, CA, USA), anti-Tim23
(BD Biosciences, San Jose, CA, USA) were used as primary
antibodies. Albumin and tubulin were used as loading controls.
Albumin was detected upon staining of the membranes with Ponceau
solution. For adiponectin multimers, serum samples (1 ml) were
prepared in non-reducing loading buffer [21] and separated in 8-15%
gradient SDS-PAGE run at +4uC and low voltage (20–40 volts). The
quantification of the membranes was completed by densitometry
analysis with Quantity One Program (Bio-Rad Laboratories,
Hercules, CA, USA). Reference samples were loaded on each gel
to allow normalization between gels. Western blot analysis was
repeated several times (3 to 7) and results are shown as the average of
signals obtained from the different gels for each sample.
Total RNA extraction and real-time RT-PCR analysis
RNA samples from adipose, muscle, and liver tissues were
extracted using RNeasy Lipid Tissue Mini Kit; RNeasy Fibrous
Tissue Mini Kit, (QIAGEN, Valencia, CA, USA); and RNA Bee
reagent (Tel-test Inc, TX, USA), respectively, followed by DNase I
treatment (Roche Diagnostics, IN). Real time RT-PCR protocol
has been described previously [16]. Cyclophilin A and b-actin
were used as housekeeping genes. Primer sequences are shown in
Table S3.
Statistical analysis
Data are expressed as mean6SE. LFD group was used as a
reference for quantitative analysis of mRNA and protein levels.
Mean results were compared between supplemented and non-
supplemented groups using a 2-tailed unpaired t-test with a
threshold for significance at 0.05.
Homeostatic model assessment (HOMA)
HOMA was calculated according to [22].
Results
FLS ameliorates metabolic abnormalities associated with
obesity
Body and tissue weights and composition. We started
FLS after obesity was induced in the high-fat fed group (Figure 1A).
Flavonoid Effects and Metabolic Status
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subgroup of mice was tested to confirm dietary effects. Indeed,
mice fed HFD exhibited elevated fasting serum levels of insulin,
glucose, leptin, TG, and impaired GTT compared to mice fed
LFD (Table S4 and Figure S1). Throughout the study, mice
steadily gained weight with significant increase on high-fat diets
(Figure 1A). Although animals on LFDC weighed less than those
on LFD, we did not observe any significant difference in body
weight by the end of the study or any difference in total weight
gain between supplemented and non-supplemented groups (data
not shown). FLS also did not affect total adiposity. However, the
analysis of organ weights revealed a significant reduction of
visceral (gonadal) fat mass in HFDC mice (Table 1). Liver and
muscle TG content was different between high- and low-fat fed
groups, as expected (Table 1). In contrast, while no differences
were detected in hepatic TG content among supplemented and
non-supplemented groups, muscle TG (Table 1 and Figure S2)
and FA (Figure S2) levels were lower in HFDC compared to the
HFD group. Liver cholesterol levels were similar, regardless of the
dietary regimen (Table 1).
Serum parameters of glucose metabolism. Fasting serum
glucose levels were similar among all groups (Table 1). GTT
showed impaired glucose sensitivity in obese mice (HFD and
HFDC), with a trend towards a reduction of glucose levels in the
HFDC group, 90 min after glucose administration (Figure 1B).
However, fasting insulin serum levels and HOMA values were
significantly reduced in HFDC vs. HFD group (Table 1).
Serum parameters of lipid metabolism. Although there
were no significant differences in fasting serum T-C and HDL-C
levels, both supplemented groups showed a trend towards a
decrease in T-C (Table 1). Of note, HFDC mice at 24 weeks of
age displayed increased serum HDL-C levels and percentage
Figure 1. Body weight changes and Glucose Tolerance Test
(GTT) in mice on different dietary regimens. A, mouse body
weight was measured weekly from 6 to 24 weeks of age. n=12 mice in
each group at 6–14 wks of age; n=8 mice in each group at 14–24 wks
of age. B, GTT in mice at 24 wks of age. Glucose (1.5 g/ kg body weight)
was injected intraperitoneally after overnight fasting (16 hours). Plasma
glucose was measured using OneTouch Ultra Glucose Meter (LifeScan)
at 0, 15, 30, 60, and 90 min after injection. Data are expressed as
means6SE. ‘P=0.06 HFDC vs. HFD, n=6–8 mice per group.
doi:10.1371/journal.pone.0024634.g001
Table 1. Body composition, tissue weight, tissue lipid
content, and fasting serum parameters of mice at 24 weeks
of age.
LFD LFDC HFD HFDC
Body composition
Body weight, g 32623 0 614 7 614 7 61
Lean mass
&,g 2 3 622 1 60.5 23632 3 61
Total fat
&,% 3 2 673 3 665 4 635 4 62
Bone mineral density
#,
mg/cm
2
5062 50.560.2 43644 7 61
Tissue weights and lipid content
Visceral fat, g 1.260.7 0.9560.4 2.460.4 1.9*60.4
Visceral fat, % 3.160.6 3.160.4 5.460.3 4.1*60.4
Mesenteric fat, g 0.3060.11 0.3260.05 1.4060.11 1.4260.09
Liver, g 1.1060.08 1.0160.02 1.960.2 1.860.2
Liver TG, mg/g tissue 16621 7 614 7 654 1 64
Liver Cholesterol, mg/g
tissue
2.460.2 2.660.1 2.760.1 3.060.2
Muscle TG, mg/g tissue 15631 5 622 8 + 22 4 * 61
Fasting serum parameters: Glucose metabolism
Glucose, mM 11.660.5 11.760.5 12.660.5 12.260.4
GTT, glucose at 90 min,
mM
13611 5 612 7 612 3 61
Insulin, ng/mL 0.360.1 0.1960.05 1.060.2 0.4*60.2
HOMA 4.061.2 2.160.5 1062 1.9*60.8
Fasting serum parameters: Lipids
TG, mg/dL 58655 8 687 7 610 5666
NEFA, mmol/L 0.8860.05 0.9160.05 1.0460.14 1.1560.06
T-C, mg/dL 14067 12364 193612 18369
HDL-C, mg/dL 90659 0 63 101661 1 8 66
(T-C)–(HDL-C), mg/dL 5065 34*629 2 696 5 * 65
HDL-C/T-C, % 6462 73*625 3 626 5 * 62
Fasting serum parameters: Adipokines
Leptin, ng/mL 7667 649 0 620 80622
Resistin, ng/mL 26623 4 653 5 652 2 * 62
Adiponectin, mg/mL 5366 74*636 5 637 9 * 64
*P,0.05 HFDC vs. HFD and LFDC vs. LFD, n=628 animals per group except in
&, where n=3. Data are expressed as mean6SE. Total fat (%) was calculated by
using body weight and body fat mass obtained from the DEXA analysis. Visceral
fat (%) was calculated by using direct weight measurements (i.e. by a scale) of
mouse body weight at sacrifice and of dissected gonadal fat.
doi:10.1371/journal.pone.0024634.t001
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and Table S4, P,0.05 and P,0.01, respectively), with no
significant difference in T-C levels. Moreover, FLS significantly
decreased atherogenic cholesterol (T-C minus HDL-C) and
elevated the percentage of HDL-C (Table 1).
Fasting serum levels of TG showed a trend towards an increase
in the HFD mice compared to all other groups, including the
HFDC group (Table 1). NEFA levels were only significantly
different between HFDC and HDF mice at baseline, (Table 1 and
Table S4, P,0.05).
Overall these data show that FLS ameliorates insulin resistance
and serum lipid profile, and also reduces visceral fat mass in obese
mice.
Serum adipokines. Given the reduced visceral adiposity
seen with FLS, we next considered changes in specific adipokines
that might be associated with this response. As expected [23],
serum leptin levels were drastically elevated in obese mice, but
with no differences upon FLS (Table 1). In contrast, serum levels
of adiponectin were significantly elevated in FLS groups, both on
low- and high-fat diets. Interestingly, adipose adiponectin mRNA
levels (Figure 2A) were significantly reduced in HFD vs. LFD
groups but not as a function of FLS.
To further investigate the pattern of circulating adiponectin we
performed various western blot analyses (Figure 2). The antibody
specific for the full-length protein revealed a doublet of bands
corresponding to adiponectin isoforms generated upon posttrans-
lational modifications (Figure 2B) [24]. This doublet showed a
significant quantitative increase in LFDC vs. LFD with no
significant difference between HFDC and HFD groups
(Figure 2A). An antibody that detects full-length and truncated
adiponectin proteins revealed minor lower molecular weight
bands in addition to the above-mentioned doublet of full-length
adiponectin (Figure 2B). The intensity of these minor bands was
reduced in all HFD samples compared to all others. The doublet
plus minor bands was quantitatively equivalent to EIA, showing
significantly elevated adiponectin levels in both supplemented
groups (Figure 2A).
Given adiponectin’s presence in the circulation as trimers (low
molecular weight, LMW), hexamers (medium molecular weight,
MMW), and high molecular weight multimers (HMW) [25,26],
serum adiponectin profile was also analyzed by non-reducing
SDS-PAGE followed by western blot analysis (Figure 2C and 2D).
Consistent with previous reports [26,27], our data also showed
reduced levels of HMW (P,0.05, HFD vs. LFD and P,0.01,
HFD vs. LFDC) and increased levels of LMW (P,0.01, HFD and
HFDC vs. LFD and LFDC) multimers in the circulation of high-
fat fed mice (Figure 2C and 2E). Moreover, MMW band was
significantly reduced in the HFD group (Figure 2C and 2E). FLS
restored the levels of both HMW and MMW complexes in obese
mice without affecting LMW. Interestingly, HMW and MMW
multimers were detected as multiple bands which possibly
correspond to a variety of complexes assembled from adiponectin
upon posttranslational modifications [24]. A variation of trimer
numbers may also contribute to the complexity of the HMW area.
Notably, gel filtration followed by Western blot analysis revealed a
ladder of multiple bands for MMW and LMW fractions [28]. Lack
of detection of multiple bands corresponding to trimer isoforms
was probably due to poor resolution in the low molecular weight
area. Notably, the non-reducing SDS-PAGE gels were run at low
voltage, a condition that is known to improve the resolution of
high molecular weight bands and reduce that of low molecular
weight bands due to diffusion (Figure 2C and 2D). Hence, the
significant decrease of LMW intensity (Figure 2C) when compared
to that of LMW on gels run at higher voltage (Figure 2D). Overall,
our data suggest that FLS restores the serum adiponectin profile
altered by high-fat feeding.
A significant reduction in serum resistin levels indicates that this
adipokine might be an additional factor underlying the improve-
ment of insulin sensitivity in HFDC compared to HFD group
(Table 1).
Effect of FLS on cholesterol metabolism in liver
Since circulating atherogenic cholesterol levels were reduced
upon FLS, we measured hepatic mRNA levels of enzymes and
transcription factors involved in cholesterol synthesis as well as
those of receptors involved in cholesterol uptake. All the genes
involved in cholesterol synthesis, with the exception of sterol
regulatory element-binding protein-2 (SREBP2), as well as the
gene encoding the low density lipoprotein receptor (LDLR) were
downregulated in obese (HFD and HFDC) vs. normal mice (LFD)
(Figure 3A and 3C). LDLR mRNA levels were also further
reduced in HFDC vs. HFD-fed mice (Figure 3C). The pattern of
LDLR protein levels mirrored that of mRNA levels in all the
groups except HFDC. Indeed, LDLR in HFDC group showed a
trend towards an increase compared to the HFD group and levels
similar to LFD and LFDC groups (Figure 3B and 3C). Moreover,
FLS significantly reduced mRNA levels of all analyzed genes in
mice maintained on the low-fat diet (Figure 3A and 3C). No
differences were observed among groups in hepatic mRNA levels
of scavenger receptor class B type I (SRBI) and lipoprotein related
protein (LRP) (data not shown).
These data suggest that the inhibition of hepatic cholesterol
synthesis (and hence its secretion) could account for the reduced
levels of circulating atherogenic cholesterol observed in LFDC
group. The lack of differences in hepatic cholesterol content
among groups (Table 1) emphasizes the complexity of the
regulatory mechanisms that maintain homeostatic levels of
cholesterol in mammalian cells [29].
Effect of FLS on lipid metabolism in muscle
To analyze the anti-atherogenic effect of FLS in obese mice, we
examined the expression levels of lipoprotein lipase (LPL), the
main enzyme involved in the catabolism of atherogenic lipopro-
teins in the periphery of the body. After overnight fasting, the pool
of atherogenic cholesterol is composed of LDL, intermediate
density lipoprotein (IDL), and very low density lipoprotein
(VLDL), which is the main carrier of TG in the fasting state.
LPL-mediated lipolysis of TG-rich lipoproteins releases free fatty
acids (FA) that are taken up locally and processed in a tissue-
specific manner [30]. Muscle LPL mRNA levels were significantly
upregulated in the HFDC group (Figure 4A), suggesting increased
VLDL catabolism, which was not accompanied by changes in the
very low density lipoprotein receptor (VLDLR) mRNA levels
(Figure 4A).
We next analyzed the expression levels of genes involved in FA
utilization in muscle. mRNA levels of the peroxisome proliferator-
activated receptor a (PPARa), the main transcription factor
controlling FA utilization [31] and the PPARc coactivator-1a,
(PGC-1a) [32], remained unaffected upon high-fat feeding
(Figure 4B), in agreement with a previous report [33]. However,
these mRNA levels were significantly elevated in muscle of HFDC
mice (Figure 4B). In agreement, expression levels of PPARa-target
genes controlling FA uptake (cluster of differentiation 36 (CD36))
[33], uptake and activation (fatty acid transport protein 1 and 4
(FATP1 and FATP4) [34], and peroxisomal and mitochondrial
b-oxidation (acyl-coenzyme A oxidase (AOX)) [35], and carnitine
palmitoyltransferases 1b and 2 (CTP1b and CTP2) [36], were
significantly elevated in HFDC group (Figure 4C, 4D). In
Flavonoid Effects and Metabolic Status
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(UCP2), which attenuates reactive oxygen species (ROS) produc-
tion thus protecting against oxidative stress [37], were also
elevated (Figure 4D). Note that muscle TG and FA levels were
reduced in HFDC compared to HFD group (Table 1 and Figure
S3). Furthermore, given the elevation of PGC-1a, a transcriptional
regulator of mitochondrial biogenesis [38,39], we measured by
western blot analysis the expression levels of TIM 23 (a subunit
of the translocase of the mitochondrial inner membrane), a
mitochondrial-specific protein whose levels correlate with mito-
chondrial number [40]. The levels of TIM23 protein, which were
significantly reduced upon high-fat feeding (HFD vs. LFD,
P,0.05), were restored to baseline with flavonoid supplementation
(HFDC vs. HFD, P,0.01; no difference between LFD and LFDC;
Figure 4E and 4F).
Overall, our data suggest that, in muscle of obese mice, FLS
increases FA utilization, as a result of increased mitochondrial
proliferation, and also increases VLDL catabolism.
FLS increases AMPK phosphorylation in
adiponectin-target tissues
The AMP-activated protein kinase (AMPK) promotes mito-
chondrial biogenesis and FA oxidation in muscle via direct
upregulation of the expression of PPARa target genes and PGC-
1a [41]. In agreement with the results shown above, we found a
significant increase in AMPK phosphorylation (phospho-AMPK/
AMPK ratio, Figure 5A and 5C) and phospho-AMPK content
with no changes in total AMPK content (AMPK/tubulin ratio,
data not shown) in muscle of HFDC mice compared to all other
groups.
AMPK phosphorylation was increased in liver of LFDC vs.
LFD mice (Figure 5B and 5C) though total AMPK was unchanged
(data not shown). In contrast, AMPK phosphorylation was not
different between HFDC and HFD groups (Figure 5B and 5C).
However, high-fat diet increased hepatic AMPK phosphoryla-
tion compared to mice on low-fat diet (Figure 5B and 5C).
Interestingly, in obese animals the elevated phospho-AMPK signal
was accompanied by reduced AMPK content with similar tubulin
levels (Figure 5B), suggesting an increased efficiency of AMPK
phosphorylation.
In conclusion, we show that the sites of AMPK activation in
adiponectin-target tissues upon FLS are different in obese and
non-obese mice. AMPK phosphorylation was significantly in-
creased in muscle of HFDC group and in liver of LFDC vs. LFD
and obese vs. non-obese mice.
Effect of FLS on visceral fat mass
To gain insights into the mechanism underlying visceral fat
reduction in HFDC group, we measured mRNA levels of genes
controlling lipolysis, lipid uptake and utilization in adipose. No
changes were observed in LPL mRNA levels in visceral fat
(Figure 6), strongly supporting the hypothesis of a muscle specific
activation of LPL. mRNA levels of CD36 and LRP were
significantly reduced in obese mice upon FLS. No changes were
observed upon FLS in mRNA levels of PPARc, the transcriptional
factor primarily responsible for adipocyte differentiation, of genes
involved in FA utilization (AOX, CPT1a, CPT2, FATP1, and
FATP4), of LDLR, SRBI, and hormone sensitive lipase, the major
gene controlling lipolysis in fat tissues [42], regardless of the
dietary regimen (data not shown).
Thus, we speculate that reduced lipid uptake is presumably the
primary cause of visceral fat reduction observed in HFDC group.
FLS affects expression levels of adiponectin receptors
only in liver
We measured the expression levels of the adiponectin receptors,
AdipR1 and AdipR2 in skeletal muscle, liver and visceral adipose.
Consistent with current knowledge [8], the expression levels of
both AdipR1 and AdipR2 were decreased in adipose tissue upon
high-fat feeding. However, no changes were observed upon FLS
(Figure S3). No differences were found in muscle for both
receptors between any groups (Figure S3). In contrast, hepatic
AdipR2 expression levels were increased in LFDC vs. LFD and
obese mice vs. non-obese (Figure S2B).
Discussion
The molecular mechanisms underlying the effects of flavonoids
have been poorly understood. Based on chemical structures [43],
the health benefits of flavonoids have been generally attributed to
their antioxidant and free radical scavenging properties. However,
most flavonoids are poorly absorbed, extensively metabolized, and
rapidly excreted from the body. Consequently, their concentration
in serum and tissues is exceedingly low for the direct antioxi-
dant activity in the periphery [3], but relatively high in the
gastrointestinal tract where they can act as local antioxidants and
antipathogenic agents [4]. However, tissue concentrations of
flavonoids can be sufficient to affect the action of enzymes,
receptors and transcription factors, and to act beyond the
gastrointestinal tract in vivo [3,4]. Growing evidence from both in
vivo and in vitro studies suggests that polyphenols from food can
function synergistically, acting on the same or multiple targets
[44].
The consumption of cranberry and cranberry products is
associated with multiple benefits to human health. Cranberry is an
abundant source of a heterogeneous group of flavonoids, including
flavonols (mainly quercetin and myricetin glycosides), anthocya-
nins, flavan-3-ols (procyanidins and a diverse group of proantho-
cyanidins with unique structural characteristics [4]), and phenolic
acids [45], which differ in bioavailability and function [4].
The original goal of our study was to evaluate the use of dietary
supplementation with cranberry flavonoids in amelioration of
metabolic abnormalities observed in obese mice, analyze their
effects in normal mice and raise possible mechanisms for how
these effects might be occurring. FLS indeed decreased serum
atherogenic cholesterol in normal mice and improved serum lipid
profile and insulin sensitivity status in obese animals. Surprisingly,
Figure 2. FLS increases adiponectin levels and restores multimers’ adiponectin profile altered by high-fat feeding. A, quantitative
analysis of adiponectin mRNA levels in visceral adipose tissue by real-time RT-PCR and adiponectin protein levels in serum by EIA or western blot
(WB). B–D, representative western blots of serum samples. 0.5 ml (B) or 1 ml (C, D) of serum was subjected to 15% (B) or 8–15% (C, D) SDS-PAGE under
reducing, heat-denaturing (B) or non-reducing, non-heat-denaturing (C, D) conditions at different voltage: 20–25 V (C), 40–45 V (D). Adiponectin was
detected using antibodies specific for both globular (g) and full-length (f) adiponectin [(g+f), B–D)] or full length [(f), B)]. Albumin was detected by
Ponceau staining (B) and used as a loading control for reducing conditions. E, quantitative analysis of adiponectin multimers in serum. Each serum
sample was analyzed 2–4 times on different western blot membranes. HMW, high molecular weight; MMW, medium molecular weight; LMW, low
molecular weight multimers. LFD group was used as a reference for quantification. Data are expressed as mean6SE. *P,0.05, **P,0.01,
#P,0.001
LFDC vs. LFD or HFDC vs. HFD; n=728 in each group. 1C, adopted from (21).
doi:10.1371/journal.pone.0024634.g002
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obese mice. Notably, an elevation in serum adiponectin levels
upon supplementation with different polyphenols was previously
reported [46–49]. Among other adipokines, adiponectin is
considered an important link between obesity and obesity-related
disorders, including atherosclerosis and insulin resistance. In our
study, the development of obesity resulted in a decline of
adiponectin mRNA levels in visceral fat not accompanied by a
reduction in circulating adiponectin protein, but rather by its
increase. It is well-described in rodent models of diet-induced
obesity that reduction in mRNA levels of adiponectin in visceral
adipose tissue does not necessarily lead to the decrease in
circulating protein levels presumably due to increase in visceral
adipose tissue mass and significant input of other fat deposits
[50–52].
Adiponectin undergoes extensive post-translational modifica-
tions that are extremely important in controlling oligomerization,
secretion, functionality, and stability of the protein [26].
Consistent with previous reports [8], we found that high-fat
feeding alters the circulating adiponectin profile. However, we also
show that these alterations are reversed by FLS. Reduced HMW
and increased LMW adiponectin multimers observed in obesity
and diabetes [26,27,53,54] have been associated with succination
of adiponectin itself [53] and chaperone proteins involved in its
maturation and secretion [26,54]. Oxidative stress in diabetes
increases the levels of protein succination [54]. Furthermore,
flavonoids elevate the levels of glutathione, the major contributor
to the intracellular redox state [55], by regulating the transcription
of enzymes involved in its synthesis [55]. Therefore, we speculate
that flavonoids can influence the plasma adiponectin profile by
affecting the plasma adiponectin profile by influencing the
adipocyte redox status altered by high-fat feeding.
In addition to intracellular posttranslational modifications,
adiponectin can also be activated in the circulation by proteolytic
cleavage [26]. This cleavage occurs at several sites of the N-
terminal collagenous domain, releasing truncated forms. The fully
truncated protein (18 kDa), globular adiponectin, is unstable and
presumably represents the active state of adiponectin in muscle
[26,56]. We hypothesize that the minor adiponectin bands
detected by western blot correspond to the initial cleavage
products (above 25 kDa). At present, we cannot establish why
the levels of truncated protein were decreased upon high-fat
feeding but restored to normal in HFDC group. This effect might
be due to increased cleavage efficiency or linked to the elevated
levels of adiponectin.
The action of adiponectin in its target tissues is mediated by its
binding to specific receptors [8]. AdipR1, a high affinity receptor
for globular adiponectin, is abundantly expressed in skeletal
muscle and liver, whereas AdipR2, predominantly expressed in
liver, binds both full-length and globular adiponectin with lower
affinity [8]. Since no differences between any groups were found in
muscle for both receptors, we assume that the availability of the
ligand, globular adiponectin (that is present in the circulation at
extremely low levels), rather than the expression level of receptors
is the limiting factor that determines adiponectin signaling in
muscle. In contrast, given 1. that the expression profile of hepatic
AdipR2 matches the profile of AMPK activation; 2. the
abundance of full-length adiponectin, the main active adiponectin
form in liver; and 3. the lower affinity of AdipR2 for its ligand,
it is likely that AdipR2 expression level rather than its ligand
availability determines adiponectin signaling in the liver.
AMPK, the main enzyme controlling cellular energy metabo-
lism, is a major downstream target of adiponectin [57]. Once
activated, AMPK switches off ATP-consuming anabolic processes
and switches on ATP-generating catabolic pathways [58]. Thus,
adiponectin signaling mediated by AMPK is known to upregulate
mitochondrial biogenesis and FA utilization in skeletal muscle and
Figure 3. FLS downregulates expression of genes involved in
hepatic cholesterol synthesis and hepatic LDL uptake in non-
obese mice in fasting state. A, real-time RT-PCR analysis of genes
involved in cholesterol synthesis and uptake in liver. B, representative
western blot for low density lipoprotein receptor (LDLR). 70 mg of liver
protein was subjected to 8% SDS-PAGE under reducing, heat-
denaturing conditions. Tubulin was used as a loading control. Each
sample was analyzed 2–4 times on different western blot membranes.
LFD group was used as a reference for quantification. C, real-time RT-
PCR analysis (mRNA) and quantification of western blot analysis (WB) for
LDLR. Data are expressed as mean6SE. *P,0.05, **P,0.01,
#P,0.001
LFDC vs. LFD or HFDC vs. HFD; n=728 in each group. Sterol-regulatory
element binding protein 2 (SREBP2); 3-hydroxy-3-methylglutaryl-Co-A
reductase (HMG-R); 3-hydroxy-3-methylglutaryl-CoA synthase (HMG-S);
farnesyl diphosphate synthase (FDS); squalene synthase (SS).
doi:10.1371/journal.pone.0024634.g003
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In our experimental model, AMPK was activated in the main
adiponectin target tissues, depending upon the metabolic status.
FLS activated AMPK in muscle of obese mice, resulting in
elevation of expression levels of PPARa target genes, including
LPL and those controlling FA utilization. Activation of PPARa
target genes is a well-documented effect of adiponectin in muscle
[8,59]. Moreover, enhanced VLDL catabolism via activation of
muscle LPL has been demonstrated upon acute adiponectin
treatment in vivo [21]. We therefore hypothesize that adiponectin
upregulates LPL expression through PPARa activation, in turn
mediated by AMPK. However, the link between adiponectin-
AMPK and PPARa remains unclear. We propose that adipo-
nectin enhances PPARa activity via AMPK through activation of
Figure 4. FLS upregulates expression of LPL and genes involved in FA utilization in muscle in obese mice. Real-time RT-PCR analysis of
lipoprotein lipase (LPL) and very low density lipoprotein receptor (VLDLR) (A), genes involved in FA utilization in muscle: transcriptional regulation (B),
free FA (FFA) uptake and activation (C), and FA oxidation (D). E, representative western blot for TIM23 (E). 50 mg of muscle protein was subjected to
15% SDS-PAGE under reducing, heat-denaturing conditions. Tubulin was used as a loading control. F, quantitative analysis of TIM23 in muscle. LFD
group was used as a reference for quantification. Data are expressed as mean6SE. *P,0.05, **P,0.01, HFDC vs. HFD n=8 in each group. Peroxisome
proliferator-activated receptor a (PPARa); PPARc coactivator-1a (PGC-1a); cluster of differentiation (CD36); fatty acid transport proteins 1 and 4
(FATP1 and FATP4); carnitine palmitoyltransferases 1b and 2(CPT1b and CPT2); uncoupling protein 2 (UCP2); acyl-coenzyme A oxidase (AOX),
translocase of the inner mitochondrial membrane (TIM23).
doi:10.1371/journal.pone.0024634.g004
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of its ligands. Adiponectin has been shown to elevate FA oxidation
in vitro by sequential activation of AMPK, p38 MAPK, and
PPARa [59]. Also, PGC-1a is a PPARa transcriptional coacti-
vator of genes encoding mitochondrial FA b-oxidation [32] and
one of the primary targets of AMPK [60]. Furthermore, PPARa is
a ligand-induced transcription factor [61] and FAs released during
the LPL-enhanced lipolysis of VLDL ensure additional positive
feedback on PPARa activity [61]. Phosphorylation of PPARa also
markedly increases coactivation by PGC-1a and significantly
enhances ligand-dependent transactivation [62]. In addition,
activated PPARa and PGC-1a regulate their own expression
[60,63,64]. Finally, it has recently been shown that, in muscle, the
binding of adiponectin to AdipR1 increases PGC-1a expres-
sion and activity through signaling cascades involving AMPK
activation [64].
Plasma TG concentrations are inversely correlated with
adiponectin levels in humans and animal models [8]. In our
experiments, the difference in fasting serum TG levels among
groups did not reach statistical significance likely due to
considerable inter-individual variability. However, even drastic
elevation of adiponectin levels only results in a moderate reduction
in fasting TG levels (40%) [21], comparable to that observed in
our study. Hydrolysis of TG in TG-rich lipoproteins is mediated
by LPL, a key enzyme in lipoprotein metabolism [30]. Upregula-
tion of LPL activity in muscle also stabilizes HDL fraction as
remnant particles released during hydrolysis of TG-rich lipopro-
teins contributing to the maturation of HDL precursors [65].
Indeed, plasma adiponectin levels are positively correlated with
levels of HDL and HDL cholesterol [66–68] and negatively
correlated with apolipoprotein A–I clearance from the circulation
and with the levels of atherogenic large VLDL and small LDL
[67]. Therefore, we propose that 1. an increase of muscle LPL
expression upon PPARa elevation resulted in accelerated VLDL
catabolism and consequently facilitated FA utilization in muscle;
2. an elevation of VLDL catabolism could be primarily respon-
sible for the significant reduction of atherogenic cholesterol and
increase of percentage of HDL cholesterol observed upon FLS in
obese mice.
Adiponectin is known to downregulate hepatic gluconeogenesis
and improve insulin sensitivity in skeletal muscle [57] by several
mechanisms activated via adiponectin/AdipR1 signaling [64].
Muscle lipid content is one of the crucial factors determining
insulin sensitivity. Indeed, in HFDC group (compared to HFD
mice), activation of AMPK pathway in skeletal muscle resulted in a
significant decrease in muscle lipid content and improved insulin
sensitivity, as indicated by the fasting insulin levels and the HOMA
index. In our model, we did not observe significant changes in
fasting glucose levels despite the increased insulin resistance
observed in HFD mice. However, this finding was not surprising.
Indeed, it is known that in mice, an overnight fast (as performed in
our study) significantly suppresses basal plasma glucose levels such
that there are no differences between high-fat diet and chow-fed
Figure 5. FLS increases AMPK phosphorylation in liver in non-
obese mice and in muscle in obese mice. A and B, representative
western blots of muscle (A) and liver (B) samples. 70 mg of total protein
was subjected to 12.5% SDS-PAGE under reducing, heat-denaturing
conditions. C, quantitative analysis of western blots, pAMPK/AMPK ratio.
Samples were repeated on different western blot membranes. LFD
group was used as a reference for quantification. Data are expressed as
mean6SE. *P,0.05, **P,0.01, LFDC vs. LFD or HFDC vs. HFD; n=326
(liver) and n=8 (muscle) in each group.
doi:10.1371/journal.pone.0024634.g005
Figure 6. FLS inhibits lipid accumulation in visceral adipose
tissue in obese mice. Real-time RT-PCR analysis of genes involved in
lipid accumulation: lipolysis (LPL), FFA uptake (CD36) and lipoprotein
uptake (LRP). LFD group was used as a reference for quantification. Data
are expressed as mean6SE. *P,0.05, HFDC vs. HFD. Lipoprotein related
protein (LRP).
doi:10.1371/journal.pone.0024634.g006
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feeders, with about 70% of their daily caloric intake occurring
during the dark cycle, and their metabolic rate is much higher
than in humans [69]. Moreover, we found a trend towards a
decrease in hepatic G6P mRNA levels in LFDC vs. LFD group
(232% LFDC vs. LFD, p=0.06), where phosphorylation of
AMPK was elevated. The lack of statistical significance might
result from compensatory mechanisms maintaining homeostatic
glucose levels during prolonged fasting periods [70].
In summary (Figure 7A), we propose that, adiponectin/AdipR1
signaling in muscle activates the AMPK pathway, resulting in
elevated transcriptional activity of PGC-1a and PPARa, and
consequently increased expression of their target genes, which
improves the plasma cholesterol profile and insulin sensitivity in
HFDC group. We cannot exclude that, in addition to the PGC-
1a/PPARa pathway, AMPK activation could also regulate FA
oxidation via ACC phosphorylation [8]. Overall, our data are in
agreement with recently published in vivo and in vitro [64,71]
studies showing that adiponectin signaling regulates mitochondrial
biogenesis and oxidative stress in skeletal muscle.
We cannot rule out that resistin, downregulated upon FLS, is an
additional player of flavonoid action. Indeed, resistin has been
shown to inhibit AMPK phosphorylation and FA utilization in
muscle [72]. However, unlike adiponectin, resistin affects FA
uptake via CD36 translocation but not its expression level [72].
Moreover, resistin has not been correlated with VLDL catabolism
[73]. Therefore, we are inclined to hypothesize that resistin is not
the primary effector of the flavonoid action in our model.
Finally, we speculate that,downregulationof cholesterolsynthesis
in the liver, which is the major site of total body cholesterol synthesis
inrodents [74],significantlyreduced plasma atherogeniccholesterol
levels in LFDC mice. Activation of AMPK in liver has been shown
to inhibit HMG-R, the rate-limiting enzyme of cholesterol synthesis
via its phosphorylation [75]. In our study, high-fat feeding and FLS
of normal mice resulted in elevation of AMPK phosphorylation in
the liver and reduced expression not only of HMG-R but also of
other key genes of the cholesterol biosynthetic pathway, such as SS,
FDS, and HMG-S. In agreement with the current notion that
excess cholesterol coordinately regulates expression of all endoplas-
mic reticulum genes involved in cholesterol synthesis pathway,
including HMG-R [29], these data support our interpretation that
cholesterol synthesis is downregulated in LFDC mice. Further
studies will be needed to unequivocally confirm this hypothesis.
Sharp, switch-like control of the SREBP pathway maintains hepatic
cholesterolcontent ina very narrow range by regulating its synthesis
and uptake [29]. Indeed, in our study, hepatic cholesterol levels did
not change regardless of the dietary regimen. Wild-type mice adapt
quickly to cholesterol rich diets and are relatively resistant to the
development of arthrosclerosis due to high level of HDL and low
level of atherogenic lipoproteins compared to humans [76,77].
Moreover, due to compensatory increase in bile synthesis [77] and
downregulation of cholesterol synthesis [77,78], wild-type mice
maintain relatively low hepatic cholesterol levels. Although we did
not enrich diet with cholesterol, mice maintained on high-fat diet
consumed more cholesterol from the food (Table S2) and showed
downregulation of the genes of the hepatic cholesterol synthesis.
Downregulation of the SREBP pathway in transgenic mice also
reduces plasma total cholesterol despite the reduction of hepatic
LDL clearance, mainly due to the decrease in HDL levels [79]. We
did not expect that the observed 30% reduction in hepatic LDLR
expression level (LFDC vs. LFD group) would have a significant
effect of serum cholesterollevels. Indeed, LDLR is expressed in liver
as well as in peripheral tissues. In our study LDLR expression levels
were similar in muscle of all groups and showed a tendency to
increase in adipose of normal mice upon FLS (+80%, LFDC vs.
LFD, p=0.08, data not shown). Moreover, LDL receptor is a key
component of the feedback regulatory mechanisms that maintain
constant levels of cholesterol within the cell, while the circulating
levels in the form of lipoproteins can largely fluctuate [80].
We cannot exclude that hepatic cholesterol uptake was elevated
in the fed state in the LFDC group. This would ultimately increase
hepatic cholesterol content and subsequently inhibit the SREBP
pathway [29]. Notably, LDLR has been shown to be upregulated
by supplementation with different flavonoids [81,82].
In the LDFC, hepatic mRNA levels of SREBP1c, the main
transcription factor involved in the regulation of FA synthesis [31],
as well as those of fatty acid synthase (FAS) were also downregulated
(Figure S4). However, the upregulation of the stearoyl-coenzyme A
desaturase (SCD) mRNA levels in this group suggests the existence
of more complex regulatory effects of flavonoids on hepatic fatty
acid synthesis that warrant further studies.
Despite the reduction in visceral fat mass and increased FA
utilization observed in HFDC group, we did not observe changes
in total adiposity. In fact, muscle TG content and net loss of
visceral adipose tissue are extremely low compared to the total
body fat mass to make this difference remarkable. Adipogenesis
does not seem to be changed in our experimental model, likely
because PPARc, as well as genes involved in lipolysis and FA b-
oxidation were not affected by FLS. Therefore our data suggest
that the reduction of visceral fat mass is mainly due to decreased
lipid uptake by adipose tissue as a result of increase of FA
utilization in skeletal muscle. We propose that activation of LPL in
muscle upon FLS makes this tissue to act as a ‘‘sink’’ for circulating
FA, thus reducing their availability for storage in adipose, the only
tissue that stores FA under normal physiological conditions. We
Figure 7. Molecular mechanisms underlying the anti-athero-
genic effects of flavonoids in normal and obese mice.
A, activation of AMPK pathway in muscle of HFDC mice. Adiponectin/
AdipR1 signaling in muscle activates the AMPK pathway, resulting in
elevated transcriptional activity of PGC-1a and PPARa, and conse-
quently increased expression of their target genes. B, molecular
mechanisms underlying the anti-atherogenic effects of flavonoids are
different in normal and obese mice.
doi:10.1371/journal.pone.0024634.g007
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depots in the body. Notably, both loss of visceral fat and
redistribution of fat from visceral into subcutaneous areas are
considered beneficial effects [83].
Overall our data demonstrate that flavonoids affect different
molecular pathways in normal versus pathological conditions
(Figure 7B). Further research is still required to establish the
primary targets of flavonoid actions in the body and the direct link
between flavonoids and the molecular pathways that we have
shown to be affected. We speculate that flavonoids could activate
internal antioxidant pathways that drastically change adiponectin
assembling in adipocytes and trigger the adiponectin pathway. We
believe that the adiponectin-driven metabolic response is one of
the previously un-recognized mechanisms of flavonoid action in
vivo, since several studies reported elevation of adiponectin levels or
improvement of mitochondrial biogenesis or similar changes in
cholesterol metabolism under supplementation with different
polyphenols [46,47–49,82,84–86].
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Figure S1 Glucose Tolerance Test (GTT) in mice at 14
weeks of age. GTT in mice at 14 wks of age. Glucose (1.5 g/ kg
body weight) was injected intraperitoneally after overnight fasting
(16 hours). Plasma glucose was measured using OneTouch Ultra
Glucose Meter (LifeScan) at 0, 15, 30, 60, and 90 min after
injection. n=324 animal per group. Data are expressed as
means6SE.
(TIF)
Figure S2 Muscle lipids in mice at 24 weeks of age. Total
lipids from liver and muscle samples were extracted according to
the Folch extraction protocol [17]. The extracts dissolved in
chloroform with 2% Triton X100 were evaporated under nitrogen
and dissolved in water followed by measurement of FA using the
HR Series NEFA-HR(2) kit (Wako Chemicals, Richmond, VA,
USA). LFD group was used as a reference for quantification.
#P,0.001 LFDC vs. LFD and HFDC vs. HFD. n=8 animal per
group. Data are expressed as means6SE.
(TIF)
Figure S3 FLS increases expression levels of hepatic
AdipoR2 in non-obese mice. Real-time RT-PCR analysis of
adiponectin receptors AdipoR1 (A) and AdipoR2 (B) in different
tissues. LFD group was used as a reference for quantification. Data
are expressed as mean6SE. *P,0.05, LFDC vs. LFD n=8 in
each group.
(DOCX)
Figure S4 FLS affects expression of genes involved in FA
synthesis in the liver of normal mice. Real-time RT-PCR
analysis of genes involved in FA synthesis in the liver. LFD group
was used as a reference for quantification. Data are expressed as
mean6SE. *P,0.05, LFDC vs. LFD n=8 in each group.
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Table S1 Flavonoid composition of cranberry extract.
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Table S3 Primer sequences for quantitative real time
PCR.
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Table S4 Body composition, tissue weight, and fasting
serum parameters of mice at 14 weeks of age.
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